CFO Joseph Wolk told the Journal that the workforce cuts come from economic pressures and the planned separation.
“We’re not immune to some of the economic pressures that are out there just like many companies are facing in many industries,” he told the Journal. “So we’re taking this opportunity to really look at the resources, how we deploy them.”
Johnson & Johnson’s split was announced in November 2021. Johnson & Johnson will continue focusing on pharmaceuticals and medical devices, including orthopedics. The new consumer health company will focus on consumer products, including bandages, lotions and Tylenol.
The separation is expected to be completed in 2023.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
